Persistence of Cardiovascular Risk After Rofecoxib Discontinuation

被引：11

作者：

Ross, Joseph S. ^{[1
,5
]}

Madigan, David ^{[6
]}

Konstam, Marvin A. ^{[7
,8
]}

Egilman, David S. ^{[9
]}

Krumholz, Harlan M. ^{[2
,3
,4
,5
]}

机构：

[1] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT 06520 USA

[2] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06520 USA

[3] Yale Univ, Sch Med, Sch Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06520 USA

[4] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program,Dept Med, New Haven, CT 06520 USA

[5] Yale New Haven Hosp Ctr Outcomes Res & Evaluat, New Haven, CT USA

[6] Columbia Univ, Dept Stat, New York, NY USA

[7] Tufts Univ, Sch Med, Dept Med, Tufts Med Ctr, Boston, MA 02111 USA

[8] Tufts Univ, Sch Med, Ctr Cardiovasc, Boston, MA 02111 USA

[9] Brown Univ, Dept Community Hlth, Providence, RI 02912 USA

来源：

ARCHIVES OF INTERNAL MEDICINE | 2010年 / 170卷 / 22期

关键词：

COGNITIVE IMPAIRMENT; TRIAL;

D O I：

10.1001/archinternmed.2010.461

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2035 / 2036

页数：2

共 5 条

[1] Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial [J].

Baron, John A. ;

Sandler, Robert S. ;

Bresalier, Robert S. ;

Lanas, Angel ;

Morton, Dion G. ;

Riddell, Robert ;

Iverson, Erik R. ;

DeMets, David L. .

LANCET, 2008, 372 (9651) :1756-1764

[2] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].

Bresalier, RS ;

Sandler, RS ;

Quan, H ;

Bolognese, JA ;

Oxenius, B ;

Horgan, K ;

Lines, C ;

Riddell, R ;

Morton, D ;

Lanas, A ;

Konstam, MA ;

Baron, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102

[3] Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment - A case study based on documents from rofecoxib litigation [J].

Psaty, Bruce M. ;

Kronmal, Richard A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (15) :1813-1817

[4] Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data Lessons for Postmarket Pharmaceutical Safety Surveillance [J].

Ross, Joseph S. ;

Madigan, David ;

Hill, Kevin P. ;

Egilman, David S. ;

Wang, Yongfei ;

Krumholz, Harlan M. .

ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (21) :1976-1985

[5] A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment [J].

Thal, LJ ;

Ferris, SH ;

Kirby, L ;

Block, GA ;

Lines, CR ;

Yuen, E ;

Assaid, C ;

Nessly, ML ;

Norman, BA ;

Baranak, CC ;

Reines, SA .

NEUROPSYCHOPHARMACOLOGY, 2005, 30 (06) :1204-1215

← 1 →